Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
1. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of about 300 mg or of aripiprazole prodrug of about 441 mg,
wherein the dose is systemically released over a period of about one month, and the patient is a CYP2D6 poor metabolizer.
2. The method of claim 1 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
3. The method of claim 2 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.
4. The method of claim 1 , wherein the aripiprazole prodrug is 7-(4-(4-(2,3-dichlorophenyl)piperazin-l-yl)butoxy)-2-oxo-3,4-dihydroquinolin-l(2H)-yl)methyl dodecanoate.
5. The method of claim 1 , wherein the patient is not concomitantly administered a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor.
6. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of 200 mg,
wherein the dose is systemically released over a period of about one month and the patient is a CYP2D6 poor metabolizer concomitantly taking a CYP3A4 inhibitor.
7. The method of claim 6 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
8. The method of claim 7 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.
9. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of 300 mg or of aripiprazole prodrug of 441 mg,
wherein the dose is systemically released over a period of about one month, and the patient has concomitant use of a strong CYP2D6 or CYP3A4 inhibitor and where an initial recommended dose for a patient with normal CYP2D6 or CYP3A4 enzyme function is 400 mg of aripiprazole or 662 mg of aripiprazole prodrug.
10. The method of claim 9 , wherein the patient is a CYP2D6 and CYP3A4 extensive metabolizer.
11. The method of claim 9 , wherein the patient's concomitant use of a strong CYP2D6 inhibitor or a strong CYP3A4 inhibitor is for at least 14 days.
12. The method of claim 9 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
13. The method of claim 11 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.
14. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of 200 mg,
wherein the patient has concomitant use of CYP2D6 and CYP3A4 inhibitors, where an initial recommended dose for a patient with normal CYP2D6 or CYP3A4 enzyme function is 400 mg, and the dose is systemically released over a period of about one month.
15. The method of claim 14 , wherein the patient's concomitant use of CYP2D6 and a CYP3A4 inhibitors is for at least 14 days.
16. The method of claim 14 , wherein the patient is a CYP2D6 and CYP3A4 extensive metabolizer.
17. The method of claim 14 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
18. The method of claim 17 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.
19. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of 198 mg,
wherein the patient has concomitant use of a strong CYP2D6 or CYP3A4 inhibitor, where an initial recommended dose for a patient with normal CYP2D6 or CYP3A4 enzyme function is 300 mg, and the dose is systemically released over a period of about one month.
20. The method of claim 19 , wherein the patient's concomitant use of a strong CYP2D6 or CYP3A4 inhibitor is for at least 14 days.
21. The method of claim 19 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
22. The method of claim 21 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.
23. A method of treating schizophrenia in a patient comprising:
intramuscularly administering to the patient a long-acting suspension of an adjusted dose of aripiprazole of 159 mg,
wherein the patient has concomitant use of CYP2D6 and CYP3A4 inhibitors, where an initial recommended dose for a patient with normal CYP2D6 or CYP3A4 enzyme function is 300 mg of aripiprazole, and the dose is systemically released over a period of about one month.
24. The method of claim 23 , wherein the patient's concomitant use of CYP2D6 and CYP3A4 inhibitors is for at least 14 days.
25. The method of claim 23 , wherein the step of intramuscularly administering is in the patient's deltoid or gluteal muscle.
26. The method of claim 25 , wherein the gluteal muscle is chosen from ventrogluteal muscle and dorsogluteal muscle.